ReviewBreast care (Basel, Switzerland)2016
Tumor-Infiltrating Lymphocytes: A Promising Biomarker in Breast Cancer.
Review in Breast care (Basel, Switzerland), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Comparative impact of tertiary lymphoid structures and tumor-infiltrating lymphocytes in cholangiocarcinoma.Journal for immunotherapy of cancer · 2025Trial
- Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2017Trial
- Evaluation of CD3 and CD20 Lymphocytes and Mast Cells in the Microenvironment of Central Giant Cell Granuloma, Peripheral Giant Cell Granuloma, and Giant Cell Tumor of Bone.Diagnostics (Basel, Switzerland) · 2025Article
- Tumor-Infiltrating Lymphocytes and Tumor Budding: Emerging Prognostic Markers in Breast Cancer.Cureus · 2025Article
- The Role of the Tumor Microenvironment (TME) in Advancing Cancer Therapies: Immune System Interactions, Tumor-Infiltrating Lymphocytes (TILs), and the Role of Exosomes and Inflammasomes.International journal of molecular sciences · 2025Review
- TOMM40 Correlates with Cholesterol and is Predictive of a Favorable Prognosis in Endometrial Carcinoma.Combinatorial chemistry & high throughput screening · 2025Article
- Programmed cell death protein 1 is a marker for neoadjuvant chemotherapy response in triple-negative breast cancer.Revista da Associacao Medica Brasileira (1992) · 2023Observational
- Article
- Current State of Knowledge on the Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Treatment: Approaches, Efficacy, and Challenges.Clinical Medicine Insights. Oncology · 2022Review
- Tumor-associated lymphocytes and macrophages are related to stromal elastosis and vascular invasion in breast cancer.The journal of pathology. Clinical research · 2021Article
- Algorithm-Based Meta-Analysis Reveals the Mechanistic Interaction of the Tumor Suppressor LIMD1 With Non-Small-Cell Lung Carcinoma.Frontiers in oncology · 2021Article
- Antitumour dendritic cell vaccination in a priming and boosting approach.Nature reviews. Drug discovery · 2020Review
- Whole-Lesion Histogram Analysis of the Apparent Diffusion Coefficient as a Quantitative Imaging Biomarker for Assessing the Level of Tumor-Infiltrating Lymphocytes: Value in Molecular Subtypes of Breast Cancer.Frontiers in oncology · 2020Article
- Tumor Infiltrating Lymphocytes in Breast Cancer Patients with Progressive Disease during Neoadjuvant Chemotherapy.Pathology oncology research : POR · 2019Article
- Bispecific therapeutic aptamers for targeted therapy of cancer: a review on cellular perspective.Journal of molecular medicine (Berlin, Germany) · 2018Review
- Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study.International journal of molecular sciences · 2017Article
- Evaluating the significance of density, localization, and PD-1/PD-L1 immunopositivity of mononuclear cells in the clinical course of lung adenocarcinoma patients with brain metastasis.Neuro-oncology · 2017Article
- Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer.Journal for immunotherapy of cancer · 2017Article
- Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions.Frontiers in oncology · 2017Review
- Immunological Mechanisms in Breast Cancer - from Bench to Bedside.Breast care (Basel, Switzerland) · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is clear evidence that the immune system plays an essential role in tumor defense. By determining tumor-infiltrating lymphocytes (TILs), the individual immunological response becomes more apparent and measurable. In breast cancer, high levels of TILs are associated with a more favorable clinical course. In this review, we describe how TILs are determined with emphasis on daily routine diagnostics. We further discuss their impact as a prognostic and predictive biomarker in the neoadjuvant and adjuvant therapy setting as well as in residual disease. We also discuss their potential future implications on further stratifying prognostic subgroups of breast cancer, thereby possibly influencing future therapy considerations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.